Callerio Foundation Onlus, Via A. Fleming 22-31, 34127, Trieste, Italy.
Dalton Trans. 2011 Sep 28;40(36):9069-75. doi: 10.1039/c1dt10522a. Epub 2011 Jul 4.
In our Dalton Transactions Perspective article entitled, 'Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929-1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era would dictate a change in the direction of the field with knowledge of the genome increasingly allowing protein targets to be identified and not simply assuming that DNA is the only relevant target of metal-based drugs. Since our article was published new insights into the mode of action of metal-based drugs have emerged making some older findings increasingly relevant to current drug design. In this article we discuss these developments in terms of what we believe should be the future direction for the field.
在我们题为“后基因组时代的基于金属的抗肿瘤药物”的《道尔顿交易观点》文章中（Dalton Trans.，2006，1929-1933），我们根据过去几十年的研究讨论了基于金属的药物。我们得出的结论是，后基因组时代将要求该领域的方向发生变化，随着对基因组的了解越来越多，人们越来越能够识别蛋白质靶标，而不仅仅是假设 DNA 是基于金属的药物的唯一相关靶标。自我们的文章发表以来，基于金属的药物作用模式的新见解已经出现，使得一些较旧的发现越来越与当前的药物设计相关。在本文中，我们根据我们认为该领域未来的方向讨论了这些发展。
